Metabolic profiling of a novel antithrombotic compound, S002‐333 and enantiomers: metabolic stability, species comparison and in vitro–in vivo extrapolation. (May 2016)
- Record Type:
- Journal Article
- Title:
- Metabolic profiling of a novel antithrombotic compound, S002‐333 and enantiomers: metabolic stability, species comparison and in vitro–in vivo extrapolation. (May 2016)
- Main Title:
- Metabolic profiling of a novel antithrombotic compound, S002‐333 and enantiomers: metabolic stability, species comparison and in vitro–in vivo extrapolation
- Authors:
- Saxena, Amrita
Valicherla, Guru R.
Jain, Girish K.
Bhatta, Rabi S.
Saxena, Anil K.
Gayen, Jiaur R. - Abstract:
- Abstract: Objective: The aim of this research work was to characterize the metabolism of S002‐333, (2‐(4'‐methoxy‐benzenesulfonyl)‐2, 3, 4, 9‐tetrahydro‐1 H ‐pyrido (3, 4‐b) indole‐3‐carboxylic acid amide) and its enantiomers, S004‐1032 ( R ‐form) and S007‐1558 ( S ‐form) in pooled human liver microsomes (PHLM) and pooled liver microsomes (LM) of rat (RLM), rabbit (RABLM), dog (DLM) and monkey (MLM). Another objective of this study was to identify suitable surrogate species to humans for further development of lead candidates. Method: In vitro metabolic stability and metabolite identification of S002‐333 and enantiomers were carried out in PHLM and LM of various species. The prediction of surrogate species and in vitro in vivo extrapolation were performed based upon the calculated in vitro intrinsic clearance ( CL int ). Results/Conclusion: The in vitro CL int values for S002‐333, S004‐1032 and S007‐1558 were 0.027 ± 0.005, 0.025 ± 0.004 and 0.036 ± 0.005 ml/min/mg, respectively, in PHLM, indicating that S007‐1558 was the most metabolically unstable of the three. The LM of other species showed similar results. A common surrogate species to humans for S002‐333 and enantiomers was predicted as rabbit where the extrapolated hepatic clearance ( CL H ) did not show a significant difference to the in vivo CL H values. However, none of the species closely mimic humans with respect to the proportion of major metabolites (M‐1–M‐4) formed in vitro . Likewise, the CL H values were alsoAbstract: Objective: The aim of this research work was to characterize the metabolism of S002‐333, (2‐(4'‐methoxy‐benzenesulfonyl)‐2, 3, 4, 9‐tetrahydro‐1 H ‐pyrido (3, 4‐b) indole‐3‐carboxylic acid amide) and its enantiomers, S004‐1032 ( R ‐form) and S007‐1558 ( S ‐form) in pooled human liver microsomes (PHLM) and pooled liver microsomes (LM) of rat (RLM), rabbit (RABLM), dog (DLM) and monkey (MLM). Another objective of this study was to identify suitable surrogate species to humans for further development of lead candidates. Method: In vitro metabolic stability and metabolite identification of S002‐333 and enantiomers were carried out in PHLM and LM of various species. The prediction of surrogate species and in vitro in vivo extrapolation were performed based upon the calculated in vitro intrinsic clearance ( CL int ). Results/Conclusion: The in vitro CL int values for S002‐333, S004‐1032 and S007‐1558 were 0.027 ± 0.005, 0.025 ± 0.004 and 0.036 ± 0.005 ml/min/mg, respectively, in PHLM, indicating that S007‐1558 was the most metabolically unstable of the three. The LM of other species showed similar results. A common surrogate species to humans for S002‐333 and enantiomers was predicted as rabbit where the extrapolated hepatic clearance ( CL H ) did not show a significant difference to the in vivo CL H values. However, none of the species closely mimic humans with respect to the proportion of major metabolites (M‐1–M‐4) formed in vitro . Likewise, the CL H values were also predicted in humans for S002‐333 and enantiomers using various mathematical models. During analysis, there was no chiral inversion evident among the individual isomers throughout in vitro and in vivo experiments. In conclusion, the in vitro results indicate a prominent role of phase I metabolism in the degradation of S002‐333 and enantiomers and predict rabbit as an alternative species to conduct further safety and efficacy studies. Copyright © 2016 John Wiley & Sons, Ltd. … (more)
- Is Part Of:
- Biopharmaceutics & drug disposition. Volume 37:Number 4(2016:May)
- Journal:
- Biopharmaceutics & drug disposition
- Issue:
- Volume 37:Number 4(2016:May)
- Issue Display:
- Volume 37, Issue 4 (2016)
- Year:
- 2016
- Volume:
- 37
- Issue:
- 4
- Issue Sort Value:
- 2016-0037-0004-0000
- Page Start:
- 185
- Page End:
- 199
- Publication Date:
- 2016-05
- Subjects:
- metabolic stability -- in vitro–in vivo extrapolation -- intrinsic clearance -- protein binding -- chiral inversion
Biopharmaceutics -- Periodicals
Drugs -- Metabolism -- Periodicals
Pharmacology -- Periodicals
Biopharmaceutics -- Periodicals
Pharmaceutical Preparations -- metabolism -- Periodicals
615.19 - Journal URLs:
- http://onlinelibrary.wiley.com/ ↗
- DOI:
- 10.1002/bdd.1995 ↗
- Languages:
- English
- ISSNs:
- 0142-2782
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2089.355000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 446.xml